Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of puerarin in preparation of drugs for preventing and/or treating pulmonary arterial hypertension and complications thereof

A technology of pulmonary arterial hypertension and puerarin, which is applied in the direction of drug combination, application, and medical formula, to restore lung tissue function, reduce mortality, and repair organ damage

Pending Publication Date: 2018-09-25
INST OF MATERIA MEDICA AN INST OF THE CHINESE ACAD OF MEDICAL SCI
View PDF7 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

After reviewing the literature, it was found that there is no literature reporting the effect and application of this compound in the treatment of pulmonary arterial hypertension.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of puerarin in preparation of drugs for preventing and/or treating pulmonary arterial hypertension and complications thereof
  • Application of puerarin in preparation of drugs for preventing and/or treating pulmonary arterial hypertension and complications thereof
  • Application of puerarin in preparation of drugs for preventing and/or treating pulmonary arterial hypertension and complications thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0044] Example 1: Puerarin significantly improved the animal survival rate of pulmonary arterial hypertension rats.

[0045] The present embodiment records the animal's body weight every day during the administration (attached figure 1 A) and survival conditions (attached figure 1 C), at the end of the experiment (the 28th day), the body weight growth results of each group of animals were counted (attached figure 1 B) and animal survival rate (Supplementary Table 1), the animal body weight is recorded every day after modeling, and it is found that the body weight growth of the modeling animal slows down, and the positive compound has a slight effect on improving the body weight. Not obvious. Survival rate curve results show (attached figure 1 C), after 11 days of monocrotaline modeling, the animals in the model group began to die, and the survival rate of the animals in the model group at the end of the experiment was only 66.7%; the positive drug bosentan could increase th...

Embodiment 2

[0048] Example 2: The effect of puerarin on reducing pulmonary artery pressure (right ventricular systolic pressure) in pulmonary hypertension rats.

[0049] Since the pulmonary arterial pressure of rats is basically the same as the systolic pressure of the right ventricle, and it is difficult to measure the pulmonary arterial pressure, in this example, the systolic pressure of the right ventricle is used instead of the pulmonary arterial pressure to evaluate the drug efficacy. The skin was first cut along the right shoulder of the rat to expose the right jugular vein. Then blunt dissection, carefully separate the right jugular vein, make a V-shaped incision after ligating the distal end, insert the elbow PE catheter filled with heparin saline into the vein, and slightly fix the catheter and blood vessel with sutures to reduce bleeding . Slowly advance the catheter and insert it into the right ventricle along the superior vena cava, taking care to avoid inserting into the axi...

Embodiment 3

[0050] Example 3: Puerarin significantly improved the right ventricular function of pulmonary hypertension rats.

[0051] At the end of the experiment, the rats were lightly anesthetized, the chest was depilated, and the coupling agent was applied to the chest after fixation. The small animal ultrasound imaging system was used to detect the cardiac function of the rats in the M-mode long-axis view (attached image 3 ), and statistically analyzed right ventricular stroke volume, right ventricular output per minute, right ventricular wall thickness, right ventricular cavity width, etc. The results showed that the right ventricular wall thickness of pulmonary hypertension rats was significantly increased, and the right ventricular cavity was enlarged. After puerarin treatment, the right ventricular hypertrophy was significantly inhibited, and the effect was significantly stronger than that of the positive drug bosentan, indicating that puerarin can significantly improve pulmonary ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to application of compound puerarin in the preparation of drugs for preventing, relieving and / or treating pulmonary arterial hypertension and complications thereof. A large amount of clinical practice shows that the puerarin is good in curative effect on the pulmonary arterial hypertension and is an ideal compound for treating the pulmonary arterial hypertension and the complications thereof, and the puerarin can be used for preparing products for preventing, relieving and / or treating lung injury diseases caused by the pulmonary arterial hypertension, chronic pneumonia and exogenous materials and unexplained pulmonary arterial pressure increasing and complications thereof such as chronic obstructive emphysema, chronic pulmonary heart disease and cardiac failure.

Description

technical field [0001] The invention relates to the new pharmacological action of the innovative drug Puerarin and the use of the puerarin in the preparation of products for preventing, alleviating and / or treating pulmonary hypertension and its complications, belonging to the technical field of innovative drugs. technical background [0002] Primary pulmonary hypertension is a rare but very serious condition. The age of its onset population is on the low side, about 75% of patients are concentrated in the age group of 20-40 years old, and about 15% of patients are under 20 years old. At present, there is still no clear conclusion on the pathogenesis of pulmonary hypertension, and primary hyperplasia of pulmonary arterioles leading to vascular occlusion may be the main cause of its pathogenesis. [0003] When pulmonary hypertension occurs, the patient will show symptoms such as dyspnea, palpitations, chest pain, hemoptysis, and syncope. In the late stage, hypoxia, right hear...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/352A61P9/12A61P11/00A61P9/00A61P9/04
CPCA23L33/00A61K31/352A23V2002/00A23V2200/314A23V2200/326
Inventor 杜冠华吕扬方莲花张丽袁天翊杨世颖陈俞材褚光松张惠芳
Owner INST OF MATERIA MEDICA AN INST OF THE CHINESE ACAD OF MEDICAL SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com